EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between antiphospholipid antibodies, rheumatic-immune inflammation, and coronary in-stent restenosis

Wenxing Mao, Zhiming Wu, You Wei, Gaofeng Wang, Ting Xiong, Pan Chang, Fei Ye

Frontiers in Cardiovascular Medicine · 14.01.2026 · 12

DOI: 10.3389/fcvm.2025.1656305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 14.01.2026. Verfasst von Wenxing Mao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiphospholipid antibodies (aPL) and systemic rheumatic-immune inflammation (RII) may be associated with angiographic in-stent restenosis (ISR) after drug-eluting stent (DES) implantation. We prospectively evaluated these associations in a large Chinese cohort of DES recipients.

Methods

In this prospective cohort, we enrolled 2,503 consecutive adults who received at least one new-generation DES between May 2022 and January 2024. Preprocedural blood samples were assessed for antiphospholipid antibodies (anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM, and lupus anticoagulant) and inflammatory biomarkers [RII; high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), erythrocyte sedimentation rate (ESR), complement C3/C4, rheumatoid factor, and anti-cyclic citrullinated peptide (anti-CCP) antibodies]. At 12 months, invasive coronary angiography or coronary CT angiography (CCTA) was used to assess ISR. All ISR analyses were restricted to participants who completed 12-month imaging (the imaging-complete cohort). Multivariable logistic regression adjusted for prespecified clinical/lesion/stent covariates and imaging modality. Model performance was compared for a Clinical model vs. an immune-enhanced model (clinical + aPL + IL-6) with internal bootstrap validation. ICA-only analyses were prespecified. Clinically driven target-lesion revascularization (TLR) was evaluated with Cox models in all enrolled patients.

Results

Of the 2,503 enrolled participants, 2,388 completed 12-month imaging, with ISR occurring in 193 participants (8.1%; 95% CI 6.9–9.1). In adjusted analyses, any aPL positivity (OR 1.92, 95% CI 1.34–2.74) and IL-6 (per doubling) (OR 1.25, 95% CI 1.10–1.42) were independently associated with ISR. Adding aPL and IL-6 improved discrimination (AUC 0.79 vs. 0.72, Δ = 0.07, p = 0.008), calibration, and reclassification (categorical NRI 0.18, integrated discrimination improvement (IDI) 0.04). Optimism-corrected AUC was 0.78. The findings were consistent in the ICA-only cohort (aPL OR 1.95; IL-6 OR 1.27). Over 12 months, TLR occurred in 100/2,503 (4.0%). aPL positivity (HR 2.08, 95% CI 1.36–3.18) and IL-6 (per doubling; HR 1.29, 95% CI 1.11–1.50) were associated with higher TLR risk.

Conclusion

Baseline aPL seropositivity and higher IL-6 were associated with 12-month ISR and clinically driven TLR. Incorporating these immune markers improves risk discrimination beyond clinical and angiographic factors. External validation and interventional studies are warranted.

Schlagwörter

Stichwörter der Autor:innen

antiphospholipid antibodiesdrug-eluting stentsimmune inflammatory profilingin-stent restenosisinterleukin-6

Autor:innen und Institutionen

  • Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Zitieren

APA

Mao, W., Wu, Z., Wei, Y., Wang, G., Xiong, T., Chang, P., & Ye, F. (2026). Association between antiphospholipid antibodies, rheumatic-immune inflammation, and coronary in-stent restenosis. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1656305

Vancouver

Mao W, Wu Z, Wei Y, Wang G, Xiong T, Chang P, et al. Association between antiphospholipid antibodies, rheumatic-immune inflammation, and coronary in-stent restenosis. Frontiers in Cardiovascular Medicine. 2026;12. doi:10.3389/fcvm.2025.1656305

BibTeX
@article{Mao2026,
  author = {Mao, Wenxing and Wu, Zhiming and Wei, You and Wang, Gaofeng and Xiong, Ting and Chang, Pan and Ye, Fei},
  title = {Association between antiphospholipid antibodies, rheumatic-immune inflammation, and coronary in-stent restenosis},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {12},
  doi = {10.3389/fcvm.2025.1656305}
}
Kostenlos starten →